|View printer-friendly version|
|Celgene Appoints Thomas O. Daniel, M.D. as President of Global Research|
SUMMIT, N.J., Dec 07, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Celgene Corporation (Nasdaq: CELG) announced that Thomas O. Daniel, M.D. has joined the Company as President of Celgene Research. Dr. Daniel brings to Celgene more than two decades of medical and pharmaceutical research experience, having most recently served as the Chief Scientific Officer at Ambryx, Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Prior to that, Dr. Daniel was Vice President of Research at Amgen Inc., where he served as Research Site Head for Amgen Seattle, as Inflammation Therapeutic Area Head, and on research and development portfolio review boards. Prior to Amgen's acquisition of Immunex, Dr. Daniel was Senior Vice President of Discovery Research at Immunex, where he consolidated and built programs in oncology and vascular biology.
"We are very pleased to welcome Dr. Daniel to Celgene," said Sol J. Barer, Ph.D., Chief Executive Officer at Celgene Corporation. "Dr. Daniel's extensive experience in oncology and immunology, coupled with a proven track record of building and leading research and development teams, provides us with valuable skills to advance our promising proprietary pipeline that embodies the future of Celgene."
As President of Celgene Global Research, Dr. Daniel will be responsible for leading the discovery, pre-clinical and early-stage clinical programs for Celgene worldwide. In this new role, Dr. Daniel will provide the strategic leadership in continuing to build a world-class pipeline and successfully translating discovery research into new clinical candidates.
Dr. Daniel was previously the K. M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University, and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel obtained his M.D. degree from UT Southwestern, trained in Internal Medicine at Massachusetts General Hospital, completed postdoctoral work in Molecular Genetics at UT Southwestern, was a Howard Hughes Medical Institute associate at UCSF, and an NIH funded investigator for 20 years at Vanderbilt. His laboratory research programs focused on cellular and receptor mechanisms regulating endothelial growth and neovascularization. He will report to Sol J. Barer, Ph.D, Chief Executive Officer of Celgene Corporation.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.
This release contains forward-looking statements which are subject to known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and other factors described in the Company's filings with the Securities and Exchange Commission such as our 10K, 10Q and 8K reports.
Robert J. Hugin, President & COO, +1-908-673-9102, or Brian P. Gill, Senior Director PR-IR, +1-908-673-9530, both of Celgene Corporation